Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2009-11-30
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A sympatholytic agent will be compared with a non-sympatholytic drug to asses the effect sympathetic activation and on the progression of kidney disease.
The effects of a sympatholytic agent on cardiovascular reactivity to various stressors wil be examined.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients
NCT03982160
Sympatholysis in Chronic Kidney Disease
NCT02411773
Telmisartan and Renal Perfusion in Patients With Metabolic Syndrome
NCT00452192
Targeting Central Pulsatile Hemodynamics in Chronic Kidney Disease
NCT02791906
Retinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease
NCT07235891
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Rilmenidine as a sympatholytic agent for three months
Rilmenidine
1 mg Rilmenidine per day versus
Arm 2
Nitrendipine as a non-sympatholytic agent for three months
Nitrendipine
20 mg Nitrendipine per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rilmenidine
1 mg Rilmenidine per day versus
Nitrendipine
20 mg Nitrendipine per day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* severe heart failure or ischemic heart disease
* patients with NYHA III-IV
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Erlangen-Nürnberg Medical School
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roland E Schmieder, MD
Role: PRINCIPAL_INVESTIGATOR
University of Erlangen-Nurnberg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Erlangen-Nuremberg, CRC, med. Clinic 4
Erlangen, Bavaria, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Re-No. 3186
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.